Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase 3 1

Status

Completed 5Unknown 2Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × BID protein, human × Clear all
NCT01856283 2021-01-13

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Niguarda Hospital

Phase 2 Completed
87 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00509821 2019-04-05

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

Eli Lilly and Company

Phase 2 Completed
60 enrolled 11 charts
CNS

Glioblastoma

NCT01243346 2018-06-28

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

Arog Pharmaceuticals, Inc.

Phase 2 Completed
20 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡